Vertex Pharmaceuticals Incorporated (VRTX) News
Track canonical SquawkNews coverage tagged to VRTX, Vertex Pharmaceuticals Incorporated. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 16 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
VRTX added to US 1 List
VRTX added to BofA's US 1 List
EQUITY | Aug 11, 2026, 10:26 AM UTC
H
VRTX Reports Q2 Revenue of $3.33B
VRTX Q2 revenue rises to $3.33B
EQUITY | Aug 03, 2026, 08:09 PM UTC
H
VRTX Reports Q2 Adj. EPS $4.73
VRTX Q2 earnings miss estimates
EARNINGS | Aug 03, 2026, 08:02 PM UTC
H
Vertex Pharmaceuticals Raises FY2026 Sales Guidance from $12.950B-$13.100B to $13.100B-$13.200B vs $13.065B Est
Vertex Pharmaceuticals (NASDAQ: VRTX ) raises FY2026 sales outlook from $12.950 billion-$13.100 billion to $13.100 billion-$13.200 billion vs $13.065 billion estimate.
EARNINGS | Aug 03, 2026, 08:01 PM UTC
H
US Stocks: Implied EPS Movers
Stocks with large implied EPS moves tonight
EARNINGS | Aug 03, 2026, 06:15 PM UTC
H
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
() -- Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather than macroeconomic factors, Morgan Stanley said in a note Tuesday. As of July 6, the NYSE Arca Pharmaceutical Index
RATES | Jul 08, 2026, 03:11 PM UTC
H
What You Missed On Wall Street On Tuesday
Stock indexes retreated amid losses for the heavyweight chip sector, making the Nasdaq the laggard, while the Dow pulled back from a record high reached in morning trading. Memory producers sank even though Samsung poste
GEOPOLITICS | Jul 07, 2026, 08:16 PM UTC
H
Midday Fly By: Wall Street starts coverage of SpaceX with bullish ratings
Stock indexes have retreated amid losses for the heavyweight chip sector and fresh deterioration in the macroeconomic backdrop. The Nasdaq was the laggard, falling over 1%, while the Dow pulled back from a record high re
MACRO | Jul 07, 2026, 03:57 PM UTC
L
Top Midday Stories: Amazon Seeking at Least $25 Billion From US Bond Sale; Fiserv Explores Sale of STAR Debit Network
() -- All three major US stock indexes were down in late-morning trading Tuesday, with the Nasdaq Composite falling 1.4%, as chip stocks sold off and SpaceX (SPCX) debuted on the Nasdaq 100. In company news, Amazon (AMZN
RATES | Jul 07, 2026, 03:43 PM UTC
H
Vertex Pharmaceuticals price target raised to $570 from $543 at RBC Capital
RBC Capital raised the firm's price target on Vertex Pharmaceuticals to $570 from $543 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector
RATES | Jul 07, 2026, 11:27 AM UTC
L
Vertex enters LOI with pan-Canadian Pharmaceutical Alliance for ALYFTREK
Vertex Pharmaceuticals signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK, a new triple combination therapy for the treatment of cystic fibrosis in patients aged 6 years and older who ha
EQUITY | Jul 06, 2026, 02:27 PM UTC
L
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
2026-07-03 08:57:20 ET Choosing between Arcutis Biotherapeutics (NASDAQ:ARQT) and
EQUITY | Jul 03, 2026, 01:02 PM UTC
L
Vertex Says Casgevy Label Expansion Opens Treatment to 5,500 More Us Children
On Thursday, the U.S. Food and Drug Administration (FDA) approved an expanded label for Vertex Pharmaceuticals Incorporated ‘s (NASDAQ: VRTX ) Casgevy (exagamglogene autotemcel). The approval allows Casgevy to be used in
GEOPOLITICS | Jul 02, 2026, 12:33 PM UTC
L
Reported Earlier, Vertex Wins FDA Approval Expanding CASGEVY Use To Children As Young As 2 With Severe Sickle Cell Disease Or Beta Thalassem
First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia - - Approximately 5,500 additional children in the U.S. are now
REGULATION | Jul 02, 2026, 07:09 AM UTC
L
FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease; The FDA Granted The Approval To Vertex Pharmaceuticals
FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease; The FDA Granted The Approval To Vertex Pharmaceuticals
REGULATION | Jul 01, 2026, 09:35 PM UTC
L
IBM, Verizon, Corning And A Health Care Stock On CNBC’s ‘Final Trades’
On CNBC’s “ Halftime Report Final Trades,” Jim Lebenthal, partner and chief market strategist at Cerity Partners, said Vertex Pharmaceuticals Inc (NASDAQ: VRTX ) is a great name to own in the health care sector. As per t
RATES | Jun 30, 2026, 11:50 AM UTC